Thirty-nine patients (53.4%) had HTB at the time of infusion; five of them progressed before or at D28 (one with a re-emergence of a CD19-negative clone and three with a CD19-positive clone, whereas the last one exhibited a lineage switch to acute myeloid leukemia). This evidence concerns the gene CD19 and acute myeloid leukemia.